Projects per year
Personal profile
Area of Expertise
Glaucoma is an eye disease commonly associated with an increase in intraocular pressure, afflicting nearly 3 million Americans and 70 million people world-wide. Current therapies are aimed at lowering intraocular pressure, however, damage to the optic nerve continues to occur despite these treatments. There is a pressing need for adjunct therapies aimed at protecting the optic nerve from further damage.
My laboratory research focuses on the development of strategies for neuroprotection in glaucoma. Specifically, we are testing various small molecules and adeno-associated viral gene therapies for their ability to attenuate neurodegeneration in animal models of glaucoma. We also aim to unravel cellular and molecular mechanisms underlying the pathophysiology of glaucoma.
Concepts/techniques: We carry out these studies using in vitro rat primary retinal ganglion cell cultures, ex vivo adult rat retinal explants, and various in vivo rodent models of glaucoma. We use visual function tests including pattern ERG and optomotor test to determine the efficacy of clinically relevant experimental pharmacotherapies.
Our ongoing studies have the potential to develop novel therapeutic agents for neuroprotection in glaucoma.
My laboratory research focuses on the development of strategies for neuroprotection in glaucoma. Specifically, we are testing various small molecules and adeno-associated viral gene therapies for their ability to attenuate neurodegeneration in animal models of glaucoma. We also aim to unravel cellular and molecular mechanisms underlying the pathophysiology of glaucoma.
Concepts/techniques: We carry out these studies using in vitro rat primary retinal ganglion cell cultures, ex vivo adult rat retinal explants, and various in vivo rodent models of glaucoma. We use visual function tests including pattern ERG and optomotor test to determine the efficacy of clinically relevant experimental pharmacotherapies.
Our ongoing studies have the potential to develop novel therapeutic agents for neuroprotection in glaucoma.
Education/Academic qualification
MS in Biochemistry & Genetics, University of Łódź
PhD in Microbiology, University of Łódź
Fingerprint Dive into the research topics where Dorota Stankowska is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 4 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Mechanisms Underlying Endothelin Mediated Neurodegeneration in Glaucoma
Krishnamoorthy, R., He, S. & Stankowska, D.
1/09/17 → 31/08/20
Project: Research
Neuroprotective targets of transcription factor Brn3b (For: Alexis Seibert)
5/06/17 → 31/05/18
Project: Research
Research Output
Endothelin-1 Mediated Decrease in Mitochondrial Gene Expression and Bioenergetics Contribute to Neurodegeneration of Retinal Ganglion Cells
Chaphalkar, R. M., Stankowska, D. L., He, S., Kodati, B., Phillips, N., Prah, J., Yang, S. & Krishnamoorthy, R. R., 1 Dec 2020, In : Scientific Reports. 10, 1, 3571.Research output: Contribution to journal › Article
Open Access
Kynurenic acid protects against ischemia/reperfusion-induced retinal ganglion cell death in mice
Nahomi, R. B., Nam, M. H., Rankenberg, J., Rakete, S., Houck, J. A., Johnson, G. C., Stankowska, D. L., Pantcheva, M. B., Maclean, P. S. & Nagaraj, R. H., 1 Mar 2020, In : International journal of molecular sciences. 21, 5, 1795.Research output: Contribution to journal › Article
Open Access
Correction: Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma (Cell Death Discovery, (2019), 5, 1, (112), 10.1038/s41420-019-0194-2)
Stankowska, D. L., Nam, M. H., Nahomi, R. B., Chaphalkar, R. M., Nandi, S. K., Fudala, R., Krishnamoorthy, R. & Nagaraj, R. H., 1 Dec 2019, In : Cell Death Discovery. 5, 1, 122.Research output: Contribution to journal › Comment/debate
Open Access
Erratum: Hybrid compound SA-2 is neuroprotective in animal models of retinal ganglion cell death (Investigative Ophthalmology and Visual Science (2019) 60 (3064–3073) DOI: 10.1167/iovs.18-25999)
Stankowska, D. L., Dibas, A., Li, L., Zhang, W., Krishnamoorthy, V. R., Chavala, S. H., Nguyen, T. P., Yorio, T., Ellis, D. Z. & Acharya, S., 1 Sep 2019, In : Investigative Ophthalmology and Visual Science. 60, 12, 1 p.Research output: Contribution to journal › Comment/debate
Open Access
Hybrid compound sa-2 is neuroprotective in animal models of retinal ganglion cell death
Stankowska, D. L., Dibas, A., Li, L., Zhang, W., Krishnamoorthy, V. R., Chavala, S. H., Nguyen, T. P., Yorio, T., Ellis, D. Z. & Acharya, S., Jul 2019, In : Investigative Ophthalmology and Visual Science. 60, 8, p. 3064-3073 10 p.Research output: Contribution to journal › Article
Open Access
1
Scopus
citations